FIG 3.

Cells with latent/episomal EBV express higher levels of KRAB-ZFPs than do lytic cells in culture and blood. (A to C) Flow cytometric analysis of latent BL cells that were left untreated (A and B, left) or treated with NaB for 24 h (A and B, right), followed by staining with human serum containing antibodies to EBV lytic antigens (x axis) and anti-SZF1 antibody (y axis) (A) or anti-ZNF557 antibody (y axis) (B), and cells that were stained with human serum lacking antibodies to EBV lytic antigens and isotype control antibody (C). Latent/refractory and lytic cells are indicated; data are representative of results from 3 independent experiments. (D to F) Peripheral blood B cells (D and E, left) and non-B cells (D and E, right) from an immunosuppressed peripheral blood stem cell transplant recipient with EBV viremia were stained with antibodies to EBV lytic antigen ZEBRA (x axis) and KRAB-ZFPs (y axis) (SZF1 [D] and ZNF557 [E]), and B cells were stained with control antibodies (F). Latent (and uninfected) cells as well as lytic cells are indicated.